The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer
Ruth Exner(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Florian Fitzal, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Rupert Bartsch(Universitätszahnklinik Wien), Margaretha Rudas(Comprehensive Cancer Center Vienna), Georg Pfeiler(Medical University of Vienna), Valesca P. Retèl(The Netherlands Cancer Institute), Martina Mittlboeck(Comprehensive Cancer Center Vienna), R. Jakesz(Comprehensive Cancer Center Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 38
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k